These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38689174)

  • 1. Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO.
    Pizzamiglio S; Ciniselli CM; de Azambuja E; Agbor-Tarh D; Moreno-Aspitia A; Suter TM; Trama A; De Santis MC; De Cecco L; Iorio MV; Silvestri M; Pruneri G; Verderio P; Di Cosimo S
    Breast Cancer Res Treat; 2024 Jul; 206(2):285-294. PubMed ID: 38689174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
    Di Cosimo S; Appierto V; Pizzamiglio S; Silvestri M; Baselga J; Piccart M; Huober J; Izquierdo M; de la Pena L; Hilbers FS; de Azambuja E; Untch M; Pusztai L; Pritchard K; Nuciforo P; Vincent-Salomon A; Symmans F; Apolone G; de Braud FG; Iorio MV; Verderio P; Daidone MG
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32085669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
    Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.
    Pizzamiglio S; Cosentino G; Ciniselli CM; De Cecco L; Cataldo A; Plantamura I; Triulzi T; El-Abed S; Wang Y; Bajji M; Nuciforo P; Huober J; Ellard SL; Rimm DL; Gombos A; Daidone MG; Verderio P; Tagliabue E; Di Cosimo S; Iorio MV
    Cancer Med; 2022 Jan; 11(2):332-339. PubMed ID: 34921525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.
    Di Cosimo S; Appierto V; Pizzamiglio S; Tiberio P; Iorio MV; Hilbers F; de Azambuja E; de la Peña L; Izquierdo M; Huober J; Baselga J; Piccart M; de Braud FG; Apolone G; Verderio P; Daidone MG
    Clin Cancer Res; 2019 Jul; 25(13):3887-3895. PubMed ID: 30814109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
    Li H; Liu J; Chen J; Wang H; Yang L; Chen F; Fan S; Wang J; Shao B; Yin D; Zeng M; Li M; Li J; Su F; Liu Q; Yao H; Su S; Song E
    Nat Commun; 2018 Apr; 9(1):1614. PubMed ID: 29691399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The MiR-200c/FOXP3 Network: A Promising Biomarker for Predicting Trastuzumab Response in HER2-Positive Breast Cancer.
    Othman MS; Elabbasy MT; Aref AM; Altaleb AA; Mohammed MH; Soliman DAM; El-Khazragy N
    Technol Cancer Res Treat; 2024; 23():15330338241292226. PubMed ID: 39429192
    [No Abstract]   [Full Text] [Related]  

  • 10. Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients.
    Kumar S; Sharawat SK; Ali A; Gaur V; Malik PS; Kumar S; Mohan A; Guleria R
    Curr Probl Cancer; 2020 Aug; 44(4):100540. PubMed ID: 32007320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioinformatic analysis of peripheral blood miRNA of breast cancer patients in relation with anthracycline cardiotoxicity.
    Yadi W; Shurui C; Tong Z; Suxian C; Qing T; Dongning H
    BMC Cardiovasc Disord; 2020 Feb; 20(1):43. PubMed ID: 32013934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer.
    Garrido-Cano I; Constâncio V; Adam-Artigues A; Lameirinhas A; Simón S; Ortega B; Martínez MT; Hernando C; Bermejo B; Lluch A; Lopes P; Henrique R; Jerónimo C; Cejalvo JM; Eroles P
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth.
    Leivonen SK; Sahlberg KK; Mäkelä R; Due EU; Kallioniemi O; Børresen-Dale AL; Perälä M
    Mol Oncol; 2014 Feb; 8(1):93-104. PubMed ID: 24148764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Circulating Mirnas Profiling for Identification of Potential Breast Cancer Early Detection Biomarkers.
    Jusoh AR; Mohan SV; Lu Ping T; Tengku Din TADAAB; Haron J; Romli RC; Jaafar H; Nafi SN; Tuan Salwani TI; Yahya MM
    Asian Pac J Cancer Prev; 2021 May; 22(5):1375-1381. PubMed ID: 34048164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients.
    Kassem NM; Makar WS; Kassem HA; Talima S; Tarek M; Hesham H; El-Desouky MA
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2749-2755. PubMed ID: 31554373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Signature of Four Circulating microRNAs as Potential Biomarkers for Diagnosing Early-Stage Breast Cancer.
    Itani MM; Nassar FJ; Tfayli AH; Talhouk RS; Chamandi GK; Itani ARS; Makoukji J; Boustany RN; Hou L; Zgheib NK; Nasr RR
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34204158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Underexpression of circulating miR-145-5p and miR-133a-3p are associated with breast cancer and immunohistochemical markers.
    García-Magallanes N; Beltran-Ontiveros SA; Leal-León EA; Luque-Ortega F; Romero-Quintana JG; Osuna-Ramirez I; Barbosa-Jasso M; Arámbula-Meraz E
    J Cancer Res Ther; 2020; 16(6):1223-1228. PubMed ID: 33342777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
    Zhang K; Wang YW; Wang YY; Song Y; Zhu J; Si PC; Ma R
    Gene; 2017 Jul; 619():10-20. PubMed ID: 28359916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
    Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of circulating MiR-30b-5p identifies advanced breast cancer.
    Estevão-Pereira H; Lobo J; Salta S; Amorim M; Lopes P; Cantante M; Reis B; Antunes L; Castro F; Palma de Sousa S; Gonçalves CS; Costa BM; Henrique R; Jerónimo C
    J Transl Med; 2019 Dec; 17(1):435. PubMed ID: 31888645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.